Neurotrophic factors loaded TGN-modified chitosan nanoparticles ameliorate symptoms of MS through GATA3/FOXP3 and targeting Th1/2 cells pathways

• Published in: Journal of drug delivery science and technology Vol. 85; p. 104570
• Main Authors: Khodakarimi, Sina, Zarebkohan, Amir, Mohaddes, Gisou, Shiri-Shahsavari, Mohammad Reza, Omrani, Mohammad Hassan, Sepasi, Tina, Beyrampour-Basmenj, Hanieh, Ebrahimi-Kalan, Abbas
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.08.2023
• Subjects: Cerebrolysin; Multiple sclerosis; Neurotrophic factor; Stem cell; Targeted delivery; TGN Peptide; Neurotrophic factor; TGN Peptide; Multiple sclerosis; Cerebrolysin; Targeted delivery; Stem cell
• ISSN: 1773-2247
• DOI: 10.1016/j.jddst.2023.104570

Two most promising treatment strategies for multiple sclerosis (MS) are the administration of mesenchymal stem cells (MSCs) and targeted delivery of cerebrolysin. Comparing these treatment plans as a source of neurotrophic factors (NTFs) can inform future MS treatment guidelines. This study was carried out on the experimental autoimmune encephalomyelitis as an animal model of MS through NTFs-loaded TGN-modified chitosan nanoparticles (NTFs@TCN) and MSCs administration. The clinical scores considerations and evaluation of biological samples were shown significant improvement in locomotion activity accompanied by a decrease in lymphocyte infiltration on spinal cord tissues in the NTFs@TCN received group. These alterations may be modulated through GATA3/FOXP3 and targeting Th1/2 cells pathways. Our data shows that the targeted drug delivery strategies and high accessibility to the central nervous system may be a suitable option in the management of MS compared to cell therapy and pure NTFs administration. [Display omitted] •NTFs nanodelivery substantially improved neuroprotection and behavioral functioning in MS.•Nanocarriers are appropriate vehicles for the delivery of neurotrophic factors and active peptides not only for MS, but also for neurological diseases.•BBB strictly limited the cerebrolysin entry into the brain by 5–10%.•TGN-modified chitosan nanoparticles have a great potential for the delivery of neurotrophic factors for the treatment of MS.